Dermatologic manifestations of colonic disorders

Current Opinion in Gastroenterology

Volumn 25, Issue 1, 2009, Pages 66-73

  Lester, Laura Umstattd ^a   Rapini, Ronald P ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NONE   (United States)

Author keywords

Degos' disease; Metastatic Crohn's disease; Muir torre syndrome

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DAPSONE; IMMUNOGLOBULIN; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; MINOCYCLINE; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE;

COLON DISEASE; CROHN DISEASE; DEBRIDEMENT; EARLY DIAGNOSIS; GENE MUTATION; MALIGNANT ATROPHIC PAPULOSIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MORTALITY; MUIR TORRE SYNDROME; REVIEW; SKIN GRANULOMA; SKIN MANIFESTATION;

COLON; COLONIC DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MASS SCREENING; MORBIDITY; SKIN; SKIN DISEASES; WORLD HEALTH;

EID: 58349094755     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32831dde71     Document Type: Review

References (49)

1. Rapini RP. Practical dermatopathology. London: Mosby; 2005. p. 416.
2. Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. London: Mosby Elsevier; 2008.
3. Demis DJ, editor. Clinical dermatology. 14th ed. Philadelphia: Harper and Row; 1987.
4. Johnston GA, Graham-Brown RAC. The skin and disorders of the alimentary tract and the hepatobiliary system. In: Freedberg IM, Eisa AZ, Wolff K, Austen KF, Goldsmith LA, Kate SI, editors. Fitzpatrick's dermatology in general medicine, 6th ed. New York: McGraw-Hill; 2003. pp. 1609-1614.
5. Champion RH, Burton JL, Bums DA, Breathnach SM, editors. The gastrointestinal tract. In: Textbook of dermatology. 6th ed. Oxford: Blackwell Science; 1998. pp. 2721-2724.
6. Schwartz RA, Torre DP. The Muir-Torre Syndrome: a 25 year retrospect. J Am Acad Dermatol 1995; 33:90-104.
7. Cesinaro AM, Ubiali A, Sighinolfi P, et al. Mismatch repair proteins expression •• and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am J Dermatopathol 2007; 29:351-358. This paper recommends screening all sebaceous neoplasms for MMR gene deficiency with IHC. It also demonstrated that approximately equal numbers of sebaceous neoplasms associated with MTS and are not positive by IHC for loss of MMR proteins. This is a much lower sensitivity of IHC detecting MTS lesions than previous studies reported. Also, it confirmed previous reports of high concordance between IHC and MSI testing, as well as between cutaneous and visceral lesions for MSI.
8. Akhtar S, Oza K, Khan SA, Wright J. Muir-Torre Syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 1999; 41:681-686.
9. Vemez M, Hutter P, Monnerat C, et al. A case of Muir-Torre syndrome • associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Caner 2007; 6:141-145. This is a case of cholangiocarcinoma as part of MTS, which is a previously unreported visceral malignancy in MTS.
10. South CD, Hampel H, Comeras I, et al. The frequency of Muir-Torre · syndrome among Lynch syndrome families. J Natl Cancer Inst 2008; 100:277-281. This study supports the overlap of MTS and HNPCC by finding that 28% of HNPCC families and 9.2% of individuals from these families also meet the clinical criteria for MTS, and recommends screening all MTS patients for HNPCC.
11. Mangold E, Rahner N, Friedrichs N, et al. MSH6 mutation in Muir-Torre •• syndrome: could this be a rare finding? Br J Dermatol 2007; 156:158-162. This paper reports the first finding of a mutation in MSH6 in a patient with MTS. They update their previous report with percentages of MTS mutations they have seen: 86% MSH2, 11% MLH1, and 1 case of MSH6.
12. Arnold A, Payne S, Fisher S, et al. An individual with Muir-Torre syndrome • found to have a pathogenic MSH6 gene mutation. Fam Cancer 2007; 6:317 - 321. This is a report of another patient with MTS having a pathogenic mutation in MSH6; they recommend screening all patients with MTS for HNPCC.
13. Chhibber V, Dresser K, Mahalingam M. MHS-6: expanding the reliability of •• immunohistochemical as a screening tool in Muir-Torre syndrome. Mod Pathol 2008; 21:159-164. This paper determined the positive predictive value of IHC screening for lack of MSH2, MLH1, and MSH6 proteins for having MTS.
14. Murphy HR, Armstrong R, Carins D, Greenhalgh KL Muir-Torre syndrome: • expanding the genotype and phenotype-a further family with a MSH6 mutation. Fam Cancer 2008. [Epub ahead of print] This paper reports another patient with MTS and MSH6 mutation, in a family with many extracolonic malignancies.
15. Mangold E, Pagenstecher C, Leister M, et al. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet 2004; 41:567-572.
16. Stella A, Surdo NC, Lastella P, et al. Germline novel MSH2 deletions and a •• founder MSH2 deletion associated with anticipation effects in HNPCC. Clin Genet 2007; 71:130-139. This paper demonstrates anticipation effect amongst 23 HNPCC parent-child pairs with MSH2 mutations, showing that the younger generation presented with cancer a median of 12 years earlier than their parents.
17. Molsein G, Tester DJ, Lindor NM, et al. Microsatellite instability and mutation analysis in hHMS2 and hHLM1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 1996; 5:1245-1252.
18. Mathiak M, Rutten A, Mangold E, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MHL1 germline mutations. Am J Surg Pathol 2002; 26:338-343.
19. Ponti G, Losi L, Di Gregorio C, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas. Cancer 2005; 103:1018-1025.
20. Entius MM, Keller JJ, Drillenberg P, et al. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 2000; 6:1784-1789.
21. Popnikolov NK, Gatalica Z, Colome-Grimmer Ml, Sanchez RL Loss of mismatch repair proteins in sebaceous gland tumors. J Cutan Pathol 2003;30:178-184.
22. Honchel R, Hailing KC, Schaid DJ, et al. Microsatellite instability in Muir-Torre syndrome. Cancer Res 1994; 54:1159-1163.
23. Yanaba K, Nakagawa H, Takeda Y, et al. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination. Br J Dermatol 2008; 158:150-256.
24. Singh RS, Grayson W, Redston M, et al. Site and tumor type predicts DNA •• mismatch repair status in cutaneous sebaceous neoplasia Am J Surg Pathol 2008; 32:936-942. This paper correlated location of tumor and type of sebaceous neoplasm with the likelihood of having MMR defects providing data to help guide clinicians on handling various sebaceous neoplasms.
25. Scheinfeld NS. Degos' disease. In: Emedicine dermatology. Last updated 2/14/2008. Available at http://www.emedicine.com/derm/topic931.htm. Accessed 6/17/2008.
26. Atchabahian A, Laisne Ml, Riche F, et al. Small bowel fistula in Degos' Disease: a case report and review of the literature. Am J Gastroenterol 1996; 91:2208-2211.
27. Katz SK, Mudd LJ, Roenigk HH Jr. Malignant atrophic papulosis (Degos' disease) involving three generations of a family. J Am Acad Dermatol 1997; 37:481-484.
28. Magrinat D, Kerwin KS, Gabriel DA. The clinical manifestations of Degos' syndrome. Arch Pathol Lab Med 1989; 113:354-362.
29. Notash A, Mazoochy H, Mirshams M, Nikoo A. Lethal systemic Degos' disease • with prominent cardiopulmonary involvement Saudi Med J 2008;29:133-137. This is a case illustrating mortality in Degos' disease as a result of cardiopulmonary involvement.
30. Wilson J, Walling WB, Stone MS. Benign cutaneous Degos' disease in a 16 •• year old girl. Pediatr Dermatol 2007; 24:18-24. This review shows that the pediatric population is affected by Degos' disease with a 58% mortality rate. They also review benign cutaneous Degos' disease in the literature, finding that this variant occurs more frequently in women, and that a significant number of patients were followed for more than 5 years without development of systemic symptoms.
31. Scheinfeld N. Malignant atrophic papulosis. Clin Exp Dermatol 2007; •• 32:483-487. This article provides a recent review of the literature on Degos' disease that goes into more depth than space allows here.
32. Harvell JD, Williford PL, White WL Benign cutaneous Degos' disease: a case report with emphasis on histopathology as papules chronologically evolve. Am J Dermatopathol 2001; 23:116-123.
33. Dego R. Malignant atrophic papulosis. Br J Dermatol 1979; 100:21-35.
34. Jalil J, Shafique M, Dar NR. Dermatological clue to diagnosis of Degos' • disease in a 2-year-old with obscure chronic abdominal pain. Clin Pediatr 2008; 47:180-182. This is a case report illustrative of gastrointestinal symptoms preceding the onset of cutaneous lesions.
35. Subramaniam K, Debinski H, Heenan P. Degos's disease with delayed involve- • merit of the gastrointestinal tract Australas J Dermatol 2008; 49:88-90. This is a case report demonstrating that gastrointestinal involvement in Degos' disease may present up to 3 years after the onset of cutaneous lesions.
36. Ojeda Cuchillero RM, Sanchez Regana M, Umbert Millet P. Benign cutaneous Degos' disease. Clin Exp Dermatol 2003; 28:145-147.
37. Subbiah P, Wijdicks E, Muenter M. Skin lesions with a fatal neurologic outcome (Degos' disease). Neurology 1996; 46:636-640.
38. Zhu KJ, Zhou Q, Lin AH, et al. The use of intravenous immunoglobulin in •• cutaneous and recurrent perforating intestinal Degos' disease (malignant atrophic papulosis). Br J Dermatol 2007; 157:206-207. This is the first report in the literature of the successful use of intravenous immunoglobulin in the treatment of cutaneous and gastrointestinal Degos' disease.
39. Friedman S, Blumber RS. Inflammatory bowel disease. In:Kasper DL, Braunwald E. Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine, 16th ed. New York: McGraw-Hill; 2005 pp. 1778-1784.
40. Greenstein AJ, Janowitz HD, Sachar DB. Extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-412.
41. Farhi D, Duriez P, Aractingi S, et al. Misleading pustular plaques on the lower • limbs during Crohn's disease: two case reports. J Med Case Rep 2007; 1:109. This is a case report demonstrating that cutaneous Crohn's lesions are often misleading causing a delay in accurate diagnosis and treatment.
42. Ploysangam T, Heubi JE, Been D, et al. Cutaneous Crohn's disease in children. J Am Acad Dermatol 1997; 36:697-704.
43. Yu JTHT, Chong LY, Lee KC. Metastatic Crohn's disease in a Chinese girl. Hong Kong Med J 2006; 12:467-469.
44. Saadah Ol, Oliver MR, Bines JE, et al. Anorectal strictures and genital Crohn's disease: an unusual clinical association. J Pediatr Gastroenterol Nutr 2003; 36:403-406.
45. Jimenez Rodriguez RM, Arguelles Solido E, Marcilla Plaza D, et al. Metastatic Crohn's disease involving the penile foreskin. Arch Esp Urol 2006; 59: 902-905.
46. Ilangovan KR, Yeo R. Unusual presentation of metastatic Crohn's. Eur J • Obstet Gynecol Reprod Biol 2008; 137:259. This is a case report demonstrating that metastatic Crohn's lesions can present even when a patient is asymptomatic as far as bowel disease is concerned.
47. Emanuel PO, Phelps RG. Metastatic Crohn's disease: a histopathologic study •• of 12 cases. J Cutan Pathol 2008; 35:457-461. This paper reviews the histopathology of 12 cases of metastatic Crohn's disease providing summation of the features typical of the cutaneous lesions, in particular distinguishing metastatic Crohn's disease from cutaneous sarcoidosis.
48. Moyes LH, Glen P, Pickford IR. Perineal metastatic Crohn's disease: a case •• report and review of the literature. Ann R Goll Surg Engl 2007; 89:W1-W3. This paper reviews six cases of perineal metastatic Crohn's disease and recommends extensive surgical debridement over medical management. They also present a case of perineal metastatic Crohn's disease that presented in a patient who had been asymptomatic for 13 years as a result of a proctocolectomy 18 years prior to the metastatic Crohn's presentation.
49. Rajpara SM, Siddha SK, Ormerod AO, et al. Cutaneous penile and perianal • Crohn's disease treated with a combination of medical and surgical interventions. Australas J Dermatol 2008; 49:21-24. This is a report of an elderly patient presenting with aggressive metastatic Crohn's disease of the penis, in whom no gastrointestinal evidence of Crohn's disease was found.